AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update

TY - JOUR

T1 - AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease

T2 - 2006 update

AU - Smith, Sidney C.

AU - Bonow, Robert O.

AU - Hutter, Adolph M.

N1 - Funding Information: Reviewers’ Disclosures Reviewer Employment Research Grant Other Research Support Speakers Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other Jonathan Abrams, MD University of New Mexico Health Science Center None None None None None None Joseph Alpert, MD University of Arizona Department of Medicine None None None None None None Jeffrey L. Anderson, MD LDS Hospital Cardiology Bristol-Myers Squibb (grant pending) None Bristol-Myers Squibb, Dia Dexus, Guilford, Merck, Johnson&Johnson/Merck, Merck-Schering, Sanofi-Aventis None Bristol-Myers Squibb, Guilford, Merck, Johnson&Johnson/Merck, Merck-Schering None Eric R. Bates, MD University of Michigan Medical Center None None None None None None Vera Bittner, MD University of Alabama at Birmingham NHLBI, Pfizer, AtheroGenics None Pfizer, Merck, Kos, Reliant None CV Therapeutics, Reliant None Ann Bolger, MD University of California San Francisco None None None None None None Roger S. Blumenthal, MD Johns Hopkins Hospital Merck, Pfizer None Pfizer, Merck, Astra Zeneca, Kos, Schering-Plough None None None Prakash Deedwania, MD University of California San Francisco Pfizer, AstraZeneca None None None Pfizer, AstraZeneca, Novartis None Mark J. Eisenberg, MD McGill University None None None None None None Gerald Fletcher, MD Mayo Clinic None None None None None None Alan D. Forker, MD St. Lukes Hospital Pfizer, Merck, Kos, Novartis, Sankyo, Bristol-Myers Squibb None Pfizer, Merck, Takeda None None None Timothy Gardner, MD Clinical Practices of the University of Pennsylvania None None None None None None Cindy L. Grines, MD William Beaumont Hospital Berlex, Pfizer, GlaxoSmithKline, Aventis, Guidant Eli Lilly, SCIMED, Johnson&Johnson, Amersham Health, Otsuka, Esperion Therapeutics, Innercool Therapies, AstraZeneca None None None Innercool Therapies, Pfizer, Sanofi-Synthelabo, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, GlaxoSmithKline Global Cardiovascular Advisory Board None Suzanne Hughes, MSN, RN None None Kos Pharmaceuticals None Guidant Corporation, Johnson&Johnson Merck Freelance writer—honoraria paid by the ACCF; Associate Editor, Cardiosource None Edgar J. Kenton, MD Lankenau Hospital None None None None None None Marian Limacher, MD University of Florida Boehringer Ingelheim NIH, NHLBI Kos Pharmaceuticals None NIH Advisory Committee on Research on Women’s Health None Jonathan R. Lindner, MD University of Virginia None None None None None None Janet B. Long, MSN, ACNP University Cardiology Foundation None None AstraZeneca None None None Patrick McBride, MD University of Wisconsin Medical School None None Kos, Merck, Pfizer, Sanyko, Schering Plough None Merck None Dale Owen, MD None None None None None None None Rita F. Redberg, MD, MSc None None None None None None None Samuel J. Shubrooks, Jr, MD Harvard Medical School None None None None None None Robert A. Vogel, MD University of Maryland Hospital Pfizer, Novartis, Schering-Plough None Pfizer, Merck None None None

PY - 2007/3

Y1 - 2007/3

UR - http://www.scopus.com/inward/record.url?scp=34247506763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247506763&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34247506763

VL - 16

SP - 60

EP - 62

JO - ACC Cardiosource Review Journal

JF - ACC Cardiosource Review Journal

SN - 1556-8571

IS - 3

ER -